Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.
TSMC Soars to Record High
Chipmaker Taiwan Semiconductor Manufacturing Co. (TSMC) [2330:TW] added some $42bn to its market value on Thursday, pushing its capitalisation to a record $575bn. This carried it past Visa [V] to become the world’s 12th most valuable firm. TSMC provides chips to Nvidia [NVDA] and Apple [AAPL]; being Taiwan’s largest company, its rally pushed the country’s benchmark index to a record high.
Microsoft Expands Footprint in Germany
At an event with Chancellor Olaf Scholz in Berlin on Thursday, Microsoft [MSFT] President Brad Smith unveiled plans to invest €3.2bn in German artificial intelligence (AI) infrastructure. “German companies are rapidly adapting AI-related technologies,” Smith said at a press conference. The funds will go towards new data centres in North Rhine-Westphalia and the Frankfurt region.
What Does Michael Burry See That No One Else Does?
Michael Burry, of The Big Short fame, upped his stake in Chinese tech giants Alibaba [BABA] and JD.com [JD] in Q4. According to its 13F filing for the period, Scion Asset Management, Burry’s investment company, now has Alibaba as its biggest holding. It remains to be seen whether these wagers will pay off: Alibaba is down 5% this year, while JD.com has fallen nearly 20%.
Nvidia Reveals AI Investments
In a 13F filing with the US Securities and Exchange Commission made on Wednesday, superstar chipmaker Nvidia revealed that, as of 31 December, it holds stakes in several smaller AI firms, among them healthcare firms Nano-X Imaging [NNOX] and Recursion [RXRX], voice AI platform SoundHound AI [SOUN], and Arm [ARM], in which Nvidia has invested $147.3m. SoundHound’s share price jumped as much as 55% on the news.
Mounjaro Lands in UK
Eli Lilly’s [LLY] obesity drug Mounjaro is being launched in the UK this week, making it the fourth European country to introduce it. Pharmacy chain Superdrug said that it would prioritise National Health Service patients, and anticipates strong demand based on the popularity of Novo Nordisk’s [NVO] Wegovy, introduced last year. In the US, meanwhile, a growing number of adolescents began taking Wegovy last year, Reuters reported.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.
Continue reading for FREE
- Includes free newsletter updates, unsubscribe anytime. Privacy policy
